Evidence map›Paper›PMID 38180993›Full record

Observational studyHepatology communications2024

Serum lactate and mean arterial pressure thresholds in patients with cirrhosis and septic shock.

Thomas N Smith, Chansong Choi, Puru Rattan, Laura Piccolo Serafim, Blake A Kassmeyer, Ryan J Lennon, Ognjen Gajic, Jody C Olson, Patrick S Kamath, Alice Gallo De Moraes and 1 more

Abstract readObservational Study
In one paragraph

Observational study in Hepatology communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Observational
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Thomas N SmithDepartment of Internal Medicine, Mayo Clinic Rochester, Rochester, Minnesota, USA.ORCID 0000-0003-2655-2826
Chansong ChoiDivision of Gastroenterology and Hepatology, Mayo Clinic Rochester, Rochester, Minnesota, USA.ORCID 0000-0003-1296-5873
Puru RattanDivision of Gastroenterology and Hepatology, Mayo Clinic Rochester, Rochester, Minnesota, USA.ORCID 0000-0001-7410-488
Laura Piccolo SerafimDivision of Pulmonary and Critical Care Medicine, Mayo Clinic Rochester, Rochester, Minnesota, USA.
Blake A KassmeyerDivision of Biomedical Statistics and Informatics, Mayo Clinic Rochester, Rochester, Minnesota, USA.
Ryan J LennonDivision of Biomedical Statistics and Informatics, Mayo Clinic Rochester, Rochester, Minnesota, USA.ORCID 0000-0002-8366-8422
Ognjen GajicDivision of Pulmonary and Critical Care Medicine, Mayo Clinic Rochester, Rochester, Minnesota, USA.ORCID 0000-0003-4218-0890
Jody C OlsonDivision of Gastroenterology and Hepatology, Mayo Clinic Rochester, Rochester, Minnesota, USA.
Patrick S KamathDivision of Gastroenterology and Hepatology, Mayo Clinic Rochester, Rochester, Minnesota, USA.ORCID 0000-0002-7888-1165
Alice Gallo De MoraesDivision of Pulmonary and Critical Care Medicine, Mayo Clinic Rochester, Rochester, Minnesota, USA.ORCID 0000-0002-5783-305
Douglas A SimonettoDivision of Gastroenterology and Hepatology, Mayo Clinic Rochester, Rochester, Minnesota, USA.ORCID 0000-0003-4095-8144

Funding

Liver Cirrhosis Network: Clinical Research Center - Mayo ClinicU01DK130181 · NIDDK · MAYO CLINIC ROCHESTER · PI VIJAY H. SHAH, Douglas A. Simonetto · 2021 to 2026
$1.9M
Randomized Placebo Controlled Pilot Trial to determine the efficacy of an IL22 agonist (F-652) in patients with Alcoholic HepatitisU01AA026886 · NIAAA · MAYO CLINIC ROCHESTER · PI SHAH, VIJAY H., SIMONETTO, DOUGLAS A. · 2018 to 2022
$375k
NIAAA NIH HHS U01 AA026886NIDDK NIH HHS U01 DK130181
6 · The paper itself

Abstract

backgroundThe Sepsis-3 guidelines have incorporated serum lactate levels of >2 mmol/L in septic shock definition to account for higher observed mortality. Further evidence is needed to support this threshold in cirrhosis, as well as target mean arterial pressure (MAP) during resuscitation.

methodsThis observational cohort study investigated the association between initial serum lactate and resuscitation MAP levels on in-hospital mortality in patients with and without cirrhosis. Patients admitted to the intensive care unit for the treatment of septic shock between 2006 and 2021 in a quaternary academic center were included. Patients with cirrhosis documented on imaging and International Classification of Disease codes (n=595) were compared to patients without cirrhosis (n=575). The association of intensive care unit admission lactate levels and median 2-hour MAP with in-hospital mortality and the need for continuous renal replacement therapy was assessed. The association between median 24-hour MAP and in-hospital mortality was analyzed post hoc.

resultsWithin the cirrhosis group, admission lactate levels of 2-4 and >4 mmol/L were associated with increased in-hospital mortality compared to lactate <2 mmol/L [adjusted odds ratio (aOR): 1.69, CI: 1.03-2.81, aOR: 4.02, CI: 2.53-6.52]. Median 24-hour MAP 60-65 and <60 mm Hg were also associated with increased in-hospital mortality compared with MAP >65 mm Hg (aOR: 2.84, CI: 1.64-4.92 and aOR: 7.34, CI: 3.17-18.76). In the noncirrhosis group, associations with in-hospital mortality were weaker for lactate 2-4 and >4 mmol/L (aOR: 1.32, CI: 0.77-2.27 and aOR: 2.25, CI: 1.40-3.67) and median 24-hour MAP 60-65 and <60 mm Hg (aOR: 1.70, CI: 0.65-4.14 and aOR: 4.41, CI: 0.79-29.38).

conclusionsThese findings support utilizing lactate >2 mmol/L in the definition of septic shock, as well as a target MAP of >65 mm Hg during resuscitation in patients with cirrhosis.

Indexed as

SepsisShock, SepticArterial PressureHumansLactic AcidLiver CirrhosisLactic Acid

Identifiers

PMID38180993
PMCPMC10781124

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.